SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it has reached a settlement in its dispute with SPKK concerning clinical trials conducted in Japan with ZADAXIN®, SciClone’s lead compound. Under this resolution, SciClone will receive $8,000,000 from SPKK.
